Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1245-1246 |
| Number of pages | 2 |
| Journal | Internal Medicine Journal |
| Volume | 44 |
| Issue number | 12a |
| DOIs | |
| Publication status | Published - Dec 2014 |
Fingerprint
Cite this
}
Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis. / Commons, Robert James; Grivas, R; Currie, Bart.
In: Internal Medicine Journal, Vol. 44, No. 12a, 12.2014, p. 1245-1246.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis
AU - Commons, Robert James
AU - Grivas, R
AU - Currie, Bart
PY - 2014/12
Y1 - 2014/12
N2 - Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
AB - Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
KW - adalimumab
KW - amoxicillin plus clavulanic acid
KW - ceftazidime
KW - cotrimoxazole
KW - doxycycline
KW - etanercept
KW - ustekinumab
KW - antiinfective agent
KW - antirheumatic agent
KW - monoclonal antibody
KW - adult
KW - agitation
KW - Article
KW - backache
KW - Burkholderia pseudomallei
KW - case report
KW - chronic pain
KW - computer assisted tomography
KW - coughing
KW - crackle
KW - disease exacerbation
KW - drug megadose
KW - drug substitution
KW - drug treatment failure
KW - drug withdrawal
KW - dyspnea
KW - eradication therapy
KW - fever
KW - headache
KW - human
KW - infection risk
KW - leukoencephalopathy
KW - male
KW - melioidosis
KW - middle aged
KW - myalgia
KW - neck pain
KW - nuclear magnetic resonance imaging
KW - psoriasis
KW - psoriatic arthritis
KW - risk assessment
KW - Arthritis, Psoriatic
KW - immunology
KW - isolation and purification
KW - microbiology
KW - risk factor
KW - treatment outcome
KW - Amoxicillin-Potassium Clavulanate Combination
KW - Anti-Infective Agents
KW - Antibodies, Monoclonal, Humanized
KW - Antirheumatic Agents
KW - Humans
KW - Male
KW - Melioidosis
KW - Middle Aged
KW - Risk Factors
KW - Treatment Outcome
KW - Trimethoprim-Sulfamethoxazole Combination
U2 - 10.1111/imj.12610
DO - 10.1111/imj.12610
M3 - Article
VL - 44
SP - 1245
EP - 1246
JO - Internal Medicine Journal
JF - Internal Medicine Journal
SN - 1444-0903
IS - 12a
ER -